10 Best Rising Penny Stocks to Buy According to Analysts

Page 9 of 9

1. Regulus Therapeutics Inc. (NASDAQ:RGLS)

Price: $1.95

1-Month Performance: 42.34%

Analyst Upside Potential: 284.62%

Number of Hedge Fund Holders: 13

Regulus Therapeutics Inc. (NASDAQ:RGLS) is another clinical-stage pharmaceutical company that engages in the development of medicines that target microRNAs to treat various unmet medical conditions. Its key focus area includes Orphan Kidney Disease with Farabursen being its main drug candidate.

On March 31, Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Regulus Therapeutics Inc. (NASDAQ:RGLS). The analyst noted that the company’s lead drug candidate for treating ADPKD showed positive results in the fourth cohort of the phase 1b study. The results indicate that the drug is effective in curbing the growth of height-adjusted total kidney volume. Moreover, Schwartz also likes the company’s engagement with the FDA which topped with the positive results points towards speedy approvals. Considering these positive factors, analysts anticipate more than 284% upside for the stock, making it the best-rising penny stock to buy according to analysts.

While we acknowledge the potential of RGLS to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RGLS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9